Technical Analysis for FPRX - Five Prime Therapeutics, Inc.

Grade Last Price % Change Price Change
B 38.0 0.03% 0.01
FPRX closed up 0.03 percent on Thursday, April 15, 2021, on 41 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat
Historical FPRX trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.69%
Boomer Buy Setup Bullish Swing Setup 0.69%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.69%
Calm After Storm Range Contraction 0.69%
Narrow Range Bar Range Contraction 0.69%
NR7 Range Contraction 0.69%
Inside Day Range Contraction 0.69%
Wide Bands Range Expansion 0.69%
Overbought Stochastic Strength 0.69%
180 Bullish Setup Bullish Swing Setup 0.40%
Older End-of-Day Signals for FPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Five Prime Therapeutics, Inc. Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company's product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Solid Tumors Monoclonal Antibodies Inflammatory Disease Cancer Cell Tyrosine Kinase Receptors Glaxosmithkline Fibroblast Growth Factor Growth Factors Gastric Cancer Fibroblast Growth Factor Receptor 2

Is FPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 38.9
52 Week Low 2.64
Average Volume 2,257,062
200-Day Moving Average 15.17
50-Day Moving Average 31.27
20-Day Moving Average 37.83
10-Day Moving Average 37.91
Average True Range 0.47
ADX 59.08
+DI 43.39
-DI 10.14
Chandelier Exit (Long, 3 ATRs ) 36.59
Chandelier Exit (Short, 3 ATRs ) 39.02
Upper Bollinger Band 38.07
Lower Bollinger Band 37.60
Percent B (%b) 0.85
BandWidth 1.26
MACD Line 1.64
MACD Signal Line 2.17
MACD Histogram -0.5375
Fundamentals Value
Market Cap 1.76 Billion
Num Shares 46.3 Million
EPS -4.49
Price-to-Earnings (P/E) Ratio -8.47
Price-to-Sales 35.65
Price-to-Book 8.39
PEG Ratio 0.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.09
Resistance 3 (R3) 38.08 38.05 38.08
Resistance 2 (R2) 38.05 38.02 38.05 38.07
Resistance 1 (R1) 38.02 38.01 38.04 38.03 38.06
Pivot Point 37.99 37.99 37.99 37.99 37.99
Support 1 (S1) 37.96 37.96 37.98 37.97 37.94
Support 2 (S2) 37.93 37.95 37.93 37.93
Support 3 (S3) 37.90 37.93 37.93
Support 4 (S4) 37.91